Table 2.

Characteristics of included studies for short-term outcome

Author and year	Country	Design	Patients (and cohort by antiplatelet drug use)	Mean age (years)	Male sex (%)	Outcome measured	Length of follow-up	Results
D’Ascenzo et al. (2019)	25 Cardio-vascular centres across nine countries (InterTAK Registry)	Multicenter observational Retrospective Cohort Study	1533 (aspirin at discharge: 1031; no antithrombotic therapy: 502)	66.4 ± 13.1	9.8	MACCE	30 days	HR 1.24 (95% CI 0.5–3.04), p = 0.64
Dias et al. (2015)	USA	Observational Retrospective Cohort Study	206 (87 aspirin alone, 1 clopidogrel alone, 88 DAPT, 30 none)	67.8	13	MACE	Index hospitalization	Single therapy: OR 0.4, 95% CI (0.16–0.9), P = 0.04; DAPT: OR 0.34, 95% CI (0.18–0.65)

MACCE major adverse cardiovascular and cerebrovascular events, HR hazard ratio, CI confidence interval, DAPT dual antiplatelet therapy, MACE major adverse cardiovascular events, OR odds ratio